A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
The aim of the trial is to assess the benefit of adding high precision radiation therapy to chemotherapy and surgery for the treatment of pancreatic cancer.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG) and NHMRC CTC
Accrual Target
120
Expected Date of Accrual
31 December 2024
Trial Chairperson
Dr Andrew Oar, Gold Coast University Hospital
Trial Contact
MASTERPLAN.study@sydney.edu.au
Clinical Trial Registration
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Related Post
10 December, 2025
Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers
SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr
9 December, 2025
TROG’s inaugural Km’s for Cancer Research brings community together to support our work
LATEST NEWS: 9 December 2025 As we wrap up